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Transplantation of porcine xenografts into human recipients is a realistic option to overcome the growing worldwide shortage of suitable
allogeneic organs. However, there remains the risk of infection by porcine endogenous retroviruses (PERVs) that cannot be eliminated like
that by other microorganisms by breeding pigs under specified pathogen-free conditions. To reduce the release of PERVs by porcine
transplants, a new approach, RNA interference (RNAi), was applied. Here, we show significant reduction of PERV expression by synthetic
short interfering RNAs (siRNAs) corresponding to different parts of the viral genes gag, pol, and env. The most inhibitory sequences were
selected and expressed as short hairpin RNAs (shRNAs) by a polymerase III vector system leading to persistent suppression of PERV
replication. Cells or organs from transgenic pigs producing such shRNAs should increase the safety of xenotransplantation.
D 2004 Elsevier Inc. All rights reserved.Keywords: Porcine endogenous retrovirus; Xenotransplantation; RNA interference; Short interfering RNAIntroduction
Xenotransplants from pigs may offer a potential solu-
tion to the lack of allotransplants (Cooper, 2003). Howev-
er, this requires prevention of the immunological rejection
and a better physiological combatibility of the xenotrans-
plant as well as prevention of transmission of porcine
microorganisms. The porcine endogenous retroviruses
(PERVs) are particularly problematic because they are
integrated into the genome of all pigs (Patience et al.,
2001) and can infect human cells in vitro (Patience et al.,
1997; Specke et al., 2001). Knock-out animals may prove
difficult to produce due to the presence of several replica-
tion-competent and numerous defective proviruses capable
of complementing each other. Although PERVs infect
human cells in vitro, no virus transmission was observed
in initial clinical xenotransplantations carried out to treat
diabetes or acute liver failure (Irgang et al., 2003; Paradis
et al., 1999). In these trials, the porcine cells were
encapsulated, the contact time was very short, or the0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: DennerJ@rki.de (J. Denner).immunosuppression of the transplant recipient was very
weak. In contrast, the conditions envisaged for future
xenotransplantation include long-term transplantation of
porcine cells or whole organs, direct contact between
porcine and human cells, and pronounced immunosuppres-
sion. In the meantime, several experimental pig to nonhu-
man primate xenotransplantations and infection experi-
ments using high doses of virus in small animals and
nonhuman primates under immunosuppression have been
performed. In none of these was transmission of PERV
observed (Denner et al., 2001; Loss et al., 2001; Specke et
al., 2000). Nevertheless, the risk of transmission of porcine
viruses to transplant recipients remains and with it the risk
of retrovirus-induced tumours or immunodeficiencies
(Denner, 1998).
To minimize the possibility of PERV transmission, dif-
ferent strategies may be developed such as the selection of
low-virus-producer animals (Oldmixon et al., 2002) or the
development of an antiviral vaccine (Fiebig et al., 2003). In
addition, new approaches such as the use of RNA interfer-
ence (RNAi), based on the sequence-specific degradation of
target mRNA induced by short double-stranded RNA, should
be followed. The mechanism of RNAi is highly conserved
among plants, flies, worms, and mammals (Caplen et al.,
A. Karlas et al. / Virology 325 (2004) 18–23 192001). After processing by the ribonuclease III (RNase III)-
like enzyme Dicer, double-stranded RNA is cleaved into
small double-stranded fragments (21–25 nt) (Hammond et
al., 2000). In the cytoplasm, these short interfering RNAs
(siRNA) interact with the RNA-induced silencing complex
(RISC), which recognises the target mRNA, homologous to
the sequence of the siRNA. Nucleases, as part of the
complex, degrade the target RNA and prevent protein
translation (Billy et al., 2001; Yang et al., 2000). Transfecting
mammalian cells with longer dsRNA (>30 nt) was found to
be problematic because the induced interferon response led
to unspecific degradation of mRNA and finally to apoptosis.
The Dicer processing step can be bypassed by transfecting
cells with synthetic siRNAs (Elbashir et al., 2001). As these
siRNAs within the cells are diluted out during cell division,
the time of gene silencing activity is limited to approximately
four to eight cell doublings (McManus et al., 2002; Stein et
al., 2003). Expressing short hairpin RNA (shRNA), which
contains a short loop sequence joining the forward and
reverse strand, can overcome this limitation. Defined shRNA
without any cap or polyA structure can be expressed by
polymerase-III-dependent promoters such as the murine or
human U6 snRNA or the human RNase P (H1) RNA
promoters (Brummelkamp et al., 2002; Paddison et al.,
2002; Paul et al., 2002; Sui et al., 2002). In addition, cells
with stable chromosomal integration and permanent inhibi-
tion of target genes can be obtained if adequate selection
markers are used.
Here, we show inhibition of the expression of PERVs by
siRNAs at the level of RNA, protein, and virus release. ThisFig. 1. Localisation and efficacy of siRNAs targeting PERV. (A) Schematic presen
and oligonucleotide primers used for detection of viral RNA in PCR assays. SD an
as measured by quantitative real-time RT-PCR after transfection of synthetic siRNA
mRNA synthesis in PERV-B-infected 293 cells transfected with an irrelevant conis to our knowledge the first report showing suppression of a
retrovirus other than HIV-1 and the first report showing
suppression of an endogenous retrovirus. The approach
could lead to the generation of transgenic pigs providing
safe xenotransplants and is therefore of considerable me-
dical importance.Results
Inhibition of PERV expression by synthetic siRNAs and
selection of potent siRNA target sequences
Synthetic siRNAs targeting the genes gag, pol, and
env of PERV were designed according to published
guidelines (Fig. 1A) (Elbashir et al., 2002). The siRNAs
gag1, gag2, pol2, pol4, and pol5 should be able to
inhibit PERV-A, PERV-B, and PERV-C due to con-
served sequences. The siRNAs pol1, pol3, env1, and
env2 are specific for PERV-B. The siRNAs were trans-
fected into PERV-B-infected 293 cells and the inhibition
of gene expression was measured by real-time reverse
transcription (RT) PCR with different primer pairs
flanking the siRNA target region (Fig. 1A). Some of
the selected siRNAs failed to induce any silencing
activity (e.g., gag1), whereas others suppressed viral
gene expression to as little as 18% (Fig. 1B). Based
on these data, the most effective inhibitory construct in
terms of silencing PERV expression (siRNA Pol2) was
selected.tation of the PERV genome with the localisation of siRNA target sequences
d SA indicate splice donor and acceptor sites. (B) Expression of viral RNA
s into PERV-B-infected human 293 kidney cells, expressed as percentage of
trol siRNA.
rologyInhibition of PERV expression after stable transfection of a
shRNA-expressing plasmid
To achieve permanent expression of this pol-specific
siRNA, oligonucleotides corresponding to the pol2 region
were ligated into the vector pSuper (Suppression of en-
dogenous RNA) containing the polymerase III H1-RNA
gene promoter (Brummelkamp et al., 2002). The plasmid
was co-transfected into PERV-B-infected 293 cells together
with the plasmid pHygEGFP expressing the enhanced
green fluorescent protein (EGFP) and providing hygrom-
ycin resistance.
Some of the isolated cell clones showed a strongly
reduced expression of p27Gag protein, as shown by Western
blot analysis. A strong reduction up to 90% was found in the
cell clone A5. Although the target region is located within
the pol gene, the degradation of the complete full-length
mRNA coding for both Gag and Pol resulted in a concom-
itant decrease of Gag protein synthesis. Because the viral
protease (also encoded by the pol gene) was silenced at the
same time, the Gag protein was not processed, leading to a
relative accumulation of the Gag precursor protein (60 kDa),
whereas the other Gag proteins partially or completely
disappeared (Fig. 2A). In addition, this effect may be
explained by the fact that core assembly needs a distinct
threshold of gag protein to occur. Because the level of Gag
was reduced by RNAi, core assembly, essential for budding
and for the proteolytic cleavage of Gag, cannot take place.
Virtually the same degree of inhibition could be demon-
strated at the RNA level (Fig. 2B). This was shown by a
quantitative real-time PCR using the primer pairs (pol2 up/
down) flanking the shRNA binding site. However, when
other oligonucleotide primers were employed located up-
and downstream of the shRNA binding site, the level of
viral RNA was not significantly higher, indicating a rapid
decay of the full-length RNA molecule by the RISC
complex.
A. Karlas et al. / Vi20Fig. 2. Inhibition of PERV p27Gag expression after stable transfection of
pSuper-pol2 shRNA. (A) Western blot assay measuring viral Gag protein in
untreated 293 cells, in PERV-B-infected 293 cells and in PERV-B-infected
293 cells stably transfected with pSuper-pol2 (cell clone A5). Gag protein
expression was significantly inhibited by the siRNA and due to the
inhibition of the viral protease, a relative accumulation of the precursor Gag
protein was observed. (B) Viral RNA was processed as measured by real
time RT-PCR with different primer pairs (gag1 up/down in violet, pol2 up/
down in green, pol3-4-5 up/down in blue). PERVexpression was calculated
as the percentage of mRNA expression in PERV-B-infected 293 cells. (C)
The expression rate of spliced and unspliced viral RNA was quantified in
PERV-B-infected 293 cells and clone A5 cells expressing pSuper-pol2
shRNAs using primers flanking the splice donor and splice acceptor site.
The results demonstrate the effective inhibition of full-length but not
spliced env RNA. (D) Immunofluorescence assays also demonstrate
significant inhibition of p27Gag expression in PERV-B-infected 293 cells
transfected with pSuper-pol2 in comparison to untreated PERV-B-infected
293 cells. Cells were treated with an antiserum against p27Gag and a
TRITC-labelled secondary antibody. The expression of EGFP indicates
stable co-transfection of pSuper-pol2 and pHygEGFP.Inhibition of expression of full-length, but not spliced env
RNA
Using a PCR method which allows to discriminate
between full-length and spliced env RNA, it was shown
that the synthesis of the spliced env mRNA was not
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cells but the full-length mRNAwas (Fig. 2C). The viral env
message is spliced in the nucleus and the viral precursor
RNA cannot be processed by the RISC complex in the
cytoplasm (Zeng and Cullen, 2002). This result also shows
that the spliced env RNA is expressed at similar levels in
PERV-B-infected 293 cells and A5 cells, indicating that the
inhibition of expression of the full-length mRNA in A5 cells
up to 14% is not due to a reduced promoter activity but due
to the expression of pol2 shRNA.
After culturing these A5 cells for several months, the
gene silencing activity was still present and the plasmid
pSuper was always detected by PCR in these cells (data not
shown). The morphology and proliferation rate of these cells
were not changed compared to the untransfected cells.
Inhibition of PERV protein expression
To confirm results showing inhibition of PERV protein
expression (Fig. 2A), an immunofluorescence assay was
performed, measuring the expression of p27Gag in PERV-
B-infected cells, in cells from clone A5 and in uninfected
293 cells (Fig. 2D). Because the A5 cells were co-trans-
fected with the plasmid pHygEGFP, these cells stably
express EGFP together with the shRNA pol2. Clone A5
cells showed a strong reduction of p27Gag expression
compared to the untreated PERV-B-infected cells and at
the same time EGFP is expressed (Fig. 2D).
Inhibition of virus release
Finally, to study the release of infectious PERV by
pSuper-pol2-transfected PERV-B-infected cells, the titres
of infectious particles in the supernatant of PERV-B-infected
cells and of clone A5 cells were determined. When equal
volumes of the supernatants produced by an equal number
of cells in the same time span were titrated on uninfected
293 cells, the TCID50/ml in the supernatant of cells express-
ing the shRNAs against PERV pol was more than 1 log
lower than that of untreated PERV-B-infected 293 cells
(TCID50/mlPERV-B = 190; TCID50/mlA5 = 17).Discussion
Using synthetic siRNAs corresponding to different parts
of the viral genes gag, pol, and env, several suitable target
regions for RNAi within the PERV genome were identified,
among them the pol2 sequence that proved to be the most
effective in reducing virus expression. This is the first report
showing suppression of a retrovirus other than HIV-1 and
the first report showing suppression of an endogenous
retrovirus. Because these experiments were performed in
PERV-infected 293 cells, which produce viral particles at a
relatively high level, the suppression of PERV by RNAi
may well be more effective in pig cell lines or primaryporcine cells producing less virus as shown previously
(Denner et al., 2001).
The RNAi strategy used here could lead to the generation
of transgenic pigs providing safe xenotransplants and is
therefore of considerable medical importance. Transgenic
mice have recently been described (Carmell et al., 2003) in
which expression of shRNA lead to the silencing of the
Neil1 gene, a DNA N-glycosylase, in all organs tested
demonstrating the feasibility of this concept. To generate
transgenic pigs expressing shRNA-pol2, a lentiviral vector
may be useful. As has been shown previously, pig strains
and single individuals from the same strain differ in their
ability to release PERV from mitogen-stimulated normal
blood cells (Tacke et al., 2003). Conventional breeding and
selection of such low-virus-producer pigs together with the
creation of transgenic animals may result in a highly
reduced PERV expression in cells and organs suitable for
safe xenotransplantations. The siRNA corresponding to a
highly conserved sequence of the pol gene of all PERVs
will also suppress expression of defective proviruses, thus
preventing complementation. To reduce the virus release
to zero, additional shRNA targeting PERV at different
conserved regions will be useful. Because the RNAi
mechanism seems to be sequence specific, gene silencing
of vital cellular proteins should not occur in transgenic
pigs, although this has still to be demonstrated experi-
mentally as some RNAi off-target effects have been
recently reported (Jackson et al., 2003). In addition to
the work on other strategies to prevent PERV transmis-
sion (Fiebig et al., 2003; Oldmixon et al., 2002; Tacke et
al., 2003), extensive virological characterisation of PERVs
adapted to human cells (Denner et al., 2003), investiga-
tion of the in vitro and in vivo host range (Denner et al.,
2001; Loss et al., 2001; Patience et al., 1997; Specke et
al., 2000, 2001), as well as sensitive and specific detec-
tion methods were developed to facilitate monitoring of
PERV transmission in future clinical xenotransplantations
(Tacke et al., 2001). Together, these investigations allow
a reliable evaluation of the potential risk of PERVs in
xenotransplantation.Materials and methods
Synthetic siRNAs
The siRNAs gag1, pol2, pol4, and pol5 were purchased
from Dharmacon (Lafayette, CO); gag2, pol1, pol3, pol4,
env1, env2, and the control siRNA (fluorescence labelled,
without significant homology to mammalian genes) from
Qiagen (Hilden, Germany).
Plasmids
The plasmid pSuper (Suppression of endogenous
RNA) was purchased from Oligoengine (Seattle, WA).
A. Karlas et al. / Virology 325 (2004) 18–2322Oligonucleotides were ordered from Sigma-Genosys (Stein-
heim, Germany): (sense: 5V-GATCCCCGGACGCTGA-
CAAATTGACTTTCAAGAGAAGTCAATTTGT-
CAGCGTCCTTT-TTGGAAA-3V and antisense 5V-AGCT-
TTTCCAAAAAGGACGCTGACAAATTGACTTCTCTT-
GAAAGTCAATTTGTCAGCGTCCGGG-3V). Oligonu-
cleotides were annealed and ligated to the plasmid pSuper,
previously digested with BglII and HindIII, resulting in
pSuper-pol2.
Cells and transfection
Uninfected and PERV-infected 293 human kidney cells
were cultured in DMEM containing 10% FCS, penicillin
(100 U/ml), and streptomycin (100 Ag/ml).
pSuper-pol2 (12 Ag) and pHygEGFP (1 Ag, BD Bio-
sciences, Franklin Lakes, NJ) plasmid DNA were trans-
fected with TransFast transfection reagent (Promega,
Madison, WI) into 5  106 PERV-infected 293 cells
according to the manufacturer’s protocol. PERV-B was
kindly provided by David Onion, Q-One Biotech Ltd,
University of Glasgow, Glasgow, UK. Forty-eight hours
post transfection, hygromycin (200 Ag/ml) was added, and
after 10 days, individual clones were isolated using cloning
discs (Sigma, Munich, Germany).
For transfection of synthetic siRNAs, 7500 cells/well
were seeded in a 96-well plate. The next day, medium was
replaced by 100-Al fresh DMEM containing 10% FCS.
siRNAs were diluted in 25 Al Opti-MEM (Invitrogen) and
1 Al of the transfection reagent GeneEraser (Stratagene, La
Jolla, CA) was added. After 15 min incubation at room
temperature, the mixture was added to the cells resulting in a
final siRNA concentration of 20 nM. All assays were
performed in triplicate.
Western blot analysis
Cells were lysed with RIPA buffer (150 mM NaCl, 10
mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1%
deoxycholate, 5 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 10 mM benzamidine, 2 Ag/ml leupeptin, 100 AM
sodium orthovanadate, 10 mM p-nitrophenylphosphate) and
proteins were subjected to preparative SDS-PAGE (10 Ag
cell lysate per lane) and transferred to PVDF membranes by
electroblotting. The level of PERV Gag expression was
analysed by Western blot techniques using a goat anti-
p27Gag antiserum (Irgang et al., 2003). Loading of equal
amounts of protein was verified using antibodies against h-
actin (Sigma).
Immunofluorescence
Stably transfected cells (2  105/well) were seeded in
a six-well plate onto glass coverslips. The next day, cells
were washed with PBS, fixed with 3% formaldehyde, and
incubated for 30 min with Triton X-100. After treatmentwith the primary (anti-p27Gag, 1:100) (Irgang et al.,
2003) and secondary antibody (anti-goat IgG TRITC
conjugate, 1:2000, Sigma) at room temperature for 1 h,
cells were covered with the ProLong Antifade Kit (Mo-
lecular Probes, Eugene, OR) and mounted on slides
upside down.
Quantitative real-time RT-PCR
Cellular RNA was extracted from PERV-infected cells
using the RNAeasy Kit (Qiagen) according to the man-
ufacturer’s protocol or (for the 96-well format) by lysing
cells with 100 Al/well ‘‘cells-to-cDNA II cell lysis
buffer’’ (Ambion, Austin, TX). DNA was removed by
adding DNaseI (Hoffmann-La Roche, Basel, Switzerland)
(0.04 U/Al final, 37 jC, 30 min), which was inactivated
by incubating at 75 jC for 10 min. cDNA from 5-
Al lysate was synthesised with the RT-Kit (Applied
Biosystems, Foster City, CA) using random decamers
(Ambion). To evaluate the degradation of PERV gag-
pol mRNA, a SYBR-Green real-time PCR was per-
formed with the real-time PCR cycler MX-4000 (Stra-
tagene) and the Brilliant SYBR Green QPCR Master-Mix
(Stratagene). The amount of gag-pol and env was calcu-
lated relatively to the level of GAPDH RNA using the
2DDCT method (Livak and Schmittgen, 2001). The
amount of PERV mRNA degradation after siRNA treat-
ment was normalised to cells transfected with the control
siRNA.
In vitro infection assay
Equal amounts of PERV-B-infected 293 cells and
PERV-B-infected 293 cells stably transfected with
pSuper-pol2 were cultured. Three days later, the superna-
tant from these cells was collected, sterile filtrated, and
incubated with 5000 uninfected 293 cells in 96-well plates
for 4 days. Supernatants were removed and cells were
lysed by three freeze–thaw cycles and 3-h incubation with
proteinase K in 1 PCR buffer at 56 jC. To inactivate
proteinase K, the plate was incubated at 95 jC for 20
min. PCR was performed using cell lysate, pol-specific
primers (Pol-PK1/6) and the AmpliTaq Gold Polymerase
(Applied Biosystems). TCID50 was calculated using the
Spearmann–Karber method. Titration was performed in
four replicates, 50 Al virus-containing supernatant was
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